

August 1, 2017



# Protalex Completes Data Analysis of Second Dose Cohort of U.S. Phase 1/2 Study of PRTX-100 in ITP

## *Enrollment of Patients in Next Higher Dose Cohort Initiated*

FLORHAM PARK, N.J.--(BUSINESS WIRE)-- Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, today announced that following completion of a planned interim analysis of safety and efficacy data from the second dose cohort, the Company is escalating the dose of PRTX-100 in its U.S. Phase 1/2 study of PRTX-100 in adults with persistent/chronic Immune Thrombocytopenia (ITP) (PRTX-100-202 Study). One of the three patients treated in the second dose cohort achieved a protocol defined platelet response. Treatment of the first patient in the third cohort at a dose of 6.0 micrograms/kg, double that of the second dose cohort of 3.0 micrograms/kg, is expected soon.

"Protalex is pleased that patient enrollment into the second dose cohort of the PRTX-100-202 Study has been completed and that one patient from the cohort responded to treatment with PRTX-100. Since responses have been observed in each of the completed cohorts, we look forward to the results of treatment in the new cohort as Protalex evaluates the activity of PRTX-100 across a broad range of doses," stated Richard J. Francovitch, Ph.D., Protalex's Vice President, ITP Programs.

The 202 Study is an open-label, dose escalating study that can enroll up to 36 patients in as many as six cohorts. Each patient will receive four weekly intravenous doses of PRTX-100 and will be monitored for up to 48 weeks thereafter. The primary study endpoint of the 202 Study is a platelet response to PRTX-100. Secondary endpoints include safety, immunogenicity, and pharmacokinetics. Enrollment is currently taking place at several study sites in the U.S.

## **About Immune Thrombocytopenia (ITP)**

ITP is an autoimmune-mediated condition characterized by bruising and increased bleeding as a result of immune-mediated accelerated destruction of platelets and impaired production of platelets. The diagnosis of ITP is based upon a low platelet count, usually less than 100,000 per microliter of blood, in the absence of other possible causes of reduced platelet numbers such as an underlying illness or medication.

## **About PRTX-100**

PRTX-100, a new generation immunomodulatory therapy, is a highly purified form of SpA,

an immunomodulatory protein known to modify aspects of the human immune system. PRTX-100 has the ability, at very low concentrations, to bind to human B-lymphocytes and macrophages and to modulate immune processes. Pre-clinical data indicate that PRTX-100 may have the potential to treat ITP by reducing the immune-mediated destruction of the platelets. The two most recently approved drugs used to treat ITP, Nplate® (romiplostin) and Promacta®/Revolade™ (eltrombopag) both increase the production of platelets but do not appear to affect the underlying platelet destruction process. The safety, tolerability, and pharmacokinetics of PRTX-100 have been characterized in five clinical studies and was recently granted Orphan Drug Designation in the U.S. and Europe for the treatment of ITP. In two Phase 1b clinical trials in adult patients with active Rheumatoid Arthritis (RA), PRTX-100 was generally safe and well tolerated at all dose levels, and at certain higher doses, more patients showed improvement in measures of RA disease activity than did patients at the lower dose or placebo cohorts. PRTX-100 is given as a short intravenous infusion.

### **About Protalex, Inc.**

Protalex, Inc. is a clinical-stage biopharmaceutical company focused on the development of a class of drugs for treating autoimmune and inflammatory diseases including RA and Immune Thrombocytopenia (ITP). In the U.S., Protalex has open IND's for the treatment of RA and ITP and in Europe, an open IMPD for ITP. Please visit the Protalex website at [www.protalex.com](http://www.protalex.com) to learn more about Protalex and its lead drug candidate, PRTX-100.

### **Forward-Looking Statements**

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the Company's actual operating or clinical results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as "believes," "belief," "expects," "expect," "intends," "intend," "anticipate," "anticipates," "plans," "plan," to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with Securities and Exchange Commission.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20170801005140/en/>

LHA

Anne Marie Fields, 212-838-3777

[afields@lhai.com](mailto:afields@lhai.com)

Source: Protalex, Inc.